WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company’s Chief Scientific Officer, Anastasia Khvorova, Ph.D., presented new pre-clinical data on novel RNAi therapeutic approaches at IBC’s TIDES Oligonucleotide and Peptide® Technology and Product Development Conference in Las Vegas, Nevada. This conference is one of the longest-running, most prestigious conferences on oligonucleotide-based therapeutics, a field of drug development that includes RNAi. The conference was not webcasted.
